Crispr Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 90 to 94.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating at the beginning of a new price run.
Looking For Winning Stocks? Try This Simple Routine
Is Crispr Therapeutics Stock A Buy?
Crispr Therapeutics stock retook its 200-day moving average in recent weeks. Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to form a chart pattern and break out. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech firm posted -53% EPS growth in its most recent report, while sales growth came in at 74%. The company is expected to report its latest earnings and sales numbers on or around Jul. 29.
Crispr Therapeutics stock holds the No. 67 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls, Dynavax Technologies and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "
Biotech And Pharmaceutical Industry And Stock News."
